Functional coding/non-coding variants in EGFR, ROS1 and ALK genes and their role in liquid biopsy as a personalized therapy.

Ergoren M., Cobanogulları H., Temel Ş. G., Mocan G.

Critical reviews in oncology/hematology, vol.156, pp.103113, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 156
  • Publication Date: 2020
  • Doi Number: 10.1016/j.critrevonc.2020.103113
  • Journal Name: Critical reviews in oncology/hematology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, EMBASE, MEDLINE
  • Page Numbers: pp.103113
  • Keywords: EGFR, ROS1, ALK, Tyrosine kinase inhibitors, Liquid biopsy, Personalized therapy, CELL LUNG-CANCER, PRECISION MEDICINE, KINASE INHIBITOR, MUTATIONS, ASSOCIATION, SENSITIVITY, TISSUE
  • Bursa Uludag University Affiliated: Yes


Personalized medicine holds promise to tailor the treatment options for patients' unique genetic make-up, behavioral and environmental background. Liquid biopsy is non-invasive technique and precise diagnosis and treatment approach. Significantly, NGS technologies have revolutionized the genomic medicine by novel identifying SNPs, indel mutations in both coding and non-coding regions and also a promising technology to accelerate the early detection and finding new biomarkers for diagnosis and treatment. The number of the bioinformatics tools have been rapidly increasing with the aim of learning more about the detected mutations either they have a pathogenic role or not. EGFR, ROS1 and ALK genes are members of the RTK family. Until now, mutations within these genes have been associated with many cancers and involved in resistance formation to TKIs. This review article summarized the findings about the mostly investigated variations in EGFR, ROS1 and ALK genes and their potential role in liquid biopsy approach.